PubMed Health⌕ Search

Biomedical subjects

H Yuasa

Publications and source records attributed to H Yuasa.

At least 307 records · Page 17Linked to original sources
PubMed1983

[Effects of extracorporeally induced systemic hyperthermia on cell-mediated immunity].

We have studied the effects of extracorporeally induced systemic hyperthermia on cell-mediated immunity in 12 patients. Also, the effect of heating and anti-cancer drugs on ADCC activity 3 Plaque forming method and 51Cr release method) and NK activity (51Cr release method. target: K-562 cells) of normal human lymphocytes was studied in vitro. The following results were obtained: Lymphocytes, T-cells and IgGFcR+ T-cells counts slightly decreased during the hyperthermotherapy in patients. During initiation of the hyperthermotherapy (Rectal temp. 41.6-41.8 degrees), ADCC activity, PHA, and Con-A induced lymphocyte blastogenesis were slightly depressed, while NK activity was slightly enhanced. At the end of the hyperthermia, ADCC activity, lymphocyte blastogenesis and NK activity were extremely depressed. In vitro, 1 hour of heating at more than 40 degrees C extremely depressed ADCC activity. By heating at 42 degrees C, ADCC activity was depressed depending on heating time, while NK activity was slightly enhanced for the first 10 minutes and then depressed depending on heating time. The administration of anti-cancer drugs (MMC, 5-FU, ADM) did not affect NK activity at all during the heating at 42 degrees C. From these results, it is highly suggested that immunopotentiators should be used during extracorporeally induced systemic hyperthermia in order to make up for the depressed cell-mediated immunity.

Adult↗
PubMed1982

Analysis of Estramustine binding protein (EBP) in rat dorsal prostate by means of high pressure liquid chromatography.

High pressure liquid chromatography (HPLC, Toyo Soda TSK-GEL G3000 SW column) was used to analyse the properties of Estramustine binding protein (EBP) in the cytosol of rat dorsal prostate. There exist in the cytosol of rat dorsal prostate two binding components having a high affinity for Estramastine. When estimated by HPLC, the molecular weights of these Estramustine binding components are 45,000-50,000 and 25,000-30,000 daltons, respectively. The binding of 3H-Estramustine to a macromolecule with a molecular weight of 25,000-30,000 is more heat labile than binding of 3H-Estramustine to a macromolecule with a molecular weight of 45,000-50,000. The present study also demonstrates that the HPLC method offers higher resolution, smaller sample size and faster analysis than other methods used in binding studies.

Animals↗
PubMed1982

Cerebrovascular moyamoya disease associated with an intracranial pseudoaneurysm. Case report.

A 51-year-old woman became unconscious 19 hours after the onset of a headache. Computerized tomography disclosed an intracerebral hematoma in the left temporal lobe, with ventricular penetration. Antiography demonstrated the characteristic appearance of cerebrovascular moyamoya disease as well as an aneurysm-like shadow in the left temporal lobe, which proved on histological examination to be a pseudoaneurysm.

Arterial Occlusive Diseases↗
PubMed1981

Mechanism of retention of estramustine in the rat prostate and results of a clinical trial of Estracyt in Japan.

To clarify the mechanism of action of Estracyt, we performed experiments using 3H-estramustine of high specific activity. 3H-Radioactivity accumulated selectively in the ventral prostate of castrated male rats after the administration of 3H-estramustine. Estramustine and its metabolites were retained in the ventral prostate for long time periods. The uptake of 3H-radioactivity was almost totally localized in the cytosol fraction, but not in a purified receptor fraction. The apparent equilibrium dissociation constant of the estramustine binding protein was 18.9 nM, and the apparent equilibrium Bmax value was 0.76 nmoles/mg of cytosol protein. In addition, we wish to report in this paper the results of clinical trials of Estracyt studied by a cooperative research group in Japan from 1977 to 1979. It was concluded that Estracyt was effective in 89% of previously untreated prostatic cancer patients and in 38% of reactivated cancer patients.

Animals↗